Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $42.6 million.

  • Contineum Therapeutics' Cash & Equivalents rose 426.01% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 426.01%. This contributed to the annual value of $21.9 million for FY2024, which is 4133.07% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Cash & Equivalents of $42.6 million as of Q3 2025, which was up 426.01% from $20.8 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Cash & Equivalents high stood at $77.2 million for Q2 2024, and its period low was $15.5 million during Q4 2023.
  • Its 3-year average for Cash & Equivalents is $32.2 million, with a median of $22.2 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 4133.07% in 2024, then crashed by 7308.82% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Cash & Equivalents stood at $15.5 million in 2023, then skyrocketed by 41.33% to $21.9 million in 2024, then soared by 94.29% to $42.6 million in 2025.
  • Its last three reported values are $42.6 million in Q3 2025, $20.8 million for Q2 2025, and $22.5 million during Q1 2025.